← Leaderboards
Pearlie K Epling-Burnette
H. Lee Moffitt Cancer Ctr &Res Inst
$8,114,398
Attributed
$9,174,628
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,174,628 · 3
VA$0 · 1
By mechanism
N01$4,954,129 · 1
R01$3,327,718 · 2
N02$892,781 · 1
I01$0 · 1
Top collaborators
- Javier Pinilla6 shared
Most similar at H. Lee Moffitt Cancer Ctr &Res Inst
Same institution · by research overlap
- Sheng Wei$1,384,846
- Pamela N Munster$9,751,345
Others in their field
Top investigators on “Syndrome”
- David Heimbrook · Leidos Biomedical Research, Inc.$365,165,418
- George R Seage · Abt Associates, Inc.$241,364,559
- Barbara Driver · Westat, Inc.$177,853,041
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$174,377,607
- Michelle Vargas · Ppd Development Lp$163,846,102
- Judith S. Currier · University Of California Los Angeles$149,333,820
Research focus
SyndromeDysmyelopoietic SyndromesLaboratoriesT-LymphocyteCellsMolecularCytopeniaDesignInhibitor/AntagonistReceptorImmunotherapyBloodCytokineT-Cell ActivationResponseAutoimmune ProcessDoseIn VitroFundingBone MarrowDiagnosisAnimal ModelCancer TherapyHematopoiesis
Grant awards (24)
IGF::OT::IGF THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, CENTRAL LAB AND BIOREPOSITORY (CLB), TASK ORDER 03, SEPTEMBER 1, 2016-FEBRUARY 28, 2018$1,186,324
N01 · FY2024 · HL · contact PI
IGF::OT::IGF THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, CENTRAL LAB AND BIOREPOSITORY (CLB), TASK ORDER 03, SEPTEMBER 1, 2016-FEBRUARY 28, 2018$222,981
N01 · FY2022 · HL · contact PI
Molecular Mechanisms of Immune Therapy for Bone Marrow Failure$0
I01 · FY2019 · VA · contact PI
Molecular Mechanisms of Immune Therapy for Bone Marrow Failure$0
I01 · FY2018 · VA · contact PI
Molecular Mechanisms of Immune Therapy for Bone Marrow Failure$0
I01 · FY2017 · VA · contact PI
IGF::OT::IGF THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY, CENTRAL LAB AND BIOREPOSITORY (CLB), TASK ORDER 03, SEPTEMBER 1, 2016-FEBRUARY 28, 2018$2,133,819
N01 · FY2016 · HL · contact PI
Molecular Mechanisms of Immune Therapy for Bone Marrow Failure$0
I01 · FY2016 · VA · contact PI
IGF::OT::IGF - THE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) NATURAL HISTORY STUDY- CENTRAL LABORATORY AND BIOREPOSITORY$1,330,145
N01 · FY2015 · HL · contact PI
IGF::OT::IGF - The National Myelodysplastic Syndromes (MDS) Natural History Study- Central Laboratory and Biorepository$80,860
N01 · FY2015 · HL · contact PI
IGF::OT::IGF - The National Myelodysplastic Syndromes (MDS) Natural History Study- Central Laboratory and Biorepository$892,781
N02 · FY2014 · HL · contact PI
Molecular Mechanism of Immune Therapy for Bone Marrow Failures$0
I01 · FY2013 · VA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$282,776
R01 · FY2012 · CA · contact PI
Molecular Mechanism of Immune Therapy for Bone Marrow Failures$0
I01 · FY2012 · VA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$283,531
R01 · FY2011 · CA · contact PI
Molecular Mechanism of Immune Therapy for Bone Marrow Failures$0
I01 · FY2011 · VA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$292,604
R01 · FY2010 · CA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$686,377
R01 · FY2009 · CA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$287,173
R01 · FY2009 · CA · contact PI
Molecular Mechanism of Immune Therapy for Bone Marrow Failures$0
I01 · FY2009 · VA · contact PI
TARGETED DRUG THERAPY FOR LGL LEUKEMIA$298,719
R01 · FY2008 · CA · contact PI
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)$288,000
R01 · FY2008 · CA · contact PI
TARGETED DRUG THERAPY FOR LGL LEUKEMIA$292,556
R01 · FY2007 · CA · contact PI
TARGETED DRUG THERAPY FOR LGL LEUKEMIA$293,055
R01 · FY2006 · CA · contact PI
TARGETED DRUG THERAPY FOR LGL LEUKEMIA$322,927
R01 · FY2005 · CA